340B Patient Definition Gets Much-Needed Update In Omnibus Guidance
This article was originally published in The Pink Sheet Daily
HRSA's long-awaited comprehensive guidance clarifies numerous program policies and procedures to help ensure integrity of the drug discount program.
You may also be interested in...
A bipartisan group of senators issues a request for information to fill gaps in their wide-ranging draft bill on the 340B program. The legislation covers the participation of contract pharmacies, eligibility of "child sites," claims transparency, abuses by pharmacy benefit managers, and a third party claims clearinghouse that would monitor for duplicate discounts.
Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.
HRSA official stresses importance “good faith” by manufacturers and purchasers to assure program integrity while key definitions remain in limbo.